Introduction
-
Immunotherapy against hematopoietic malignancies using a patient’s own T-cells modified with chimeric antigen receptor (CAR-T) has exhibited dramatic success. Unfortunately, CAR-T potency against solid tumors has lagged, potentially due to insufficient T-cell expansion and persistence.
Watch our webinar, presented by Dr. Eva Morshcl, Research Scientist at Bellicum Pharmaceutical, where she shared research on drug-controlled molecular switches to improve CAR-T anti-tumor efficacy and mitigate toxicity. The presentation discussed:
- CAR-T cell therapy and its challenges in treating solid tumors
- How drug-controlled molecular switches modify CAR-T cell behavior
- How tumor growth and CAR-T cell proliferation or elimination was monitored in parallel using in vivo bioluminescent imaging